Clinical characteristics among patients with hepatocellular carcinoma according to the serum levels of alpha-fetoprotein and des-y-carboxy prothrombin

[Guest guest]

Hepatogastroenterology. 2003 Nov-Dec;50(54):2072-8.

Clinical characteristics among patients with hepatocellular carcinoma

according to the serum levels of alpha-fetoprotein and des-y-carboxy

prothrombin.

Dohmen K, Shigematsu H, Irie K, Ishibashi H.

Clinical Research Center, National Nagasaki Medical Center, Nagasaki

856-8562, Japan. dohmenk@...

BACKGROUND/AIMS: Only limited amounts of data are available at present

regarding the clinical differences in cases of hepatocellular carcinoma who

have seropositivity or seronegativity for AFP (alpha-fetoprotein) and DCP

(des-y-carboxy prothrombin). In the current study we investigated the

different clinical variables in patients with hepatocellular carcinoma

according to the serum levels of AFP and DCP. METHODOLOGY: Analyses were

performed based on 168 consecutive patients with hepatocellular carcinoma

observed for 4 years between July 1997 and December 2000 at the Internal

Medicine Department, Saga Prefectural Hospital Koseikan. They were

retrospectively evaluated for the analysis in the study. They were

classified into four groups according to their serum levels of positivity

for AFP and DCP as follows: a Negative group; seronegative for both AFP

below 20 ng/mL and DCP below 40mAU/mL, an AFP group; seropositive for AFP

above 100 ng/mL and seronegative for DCP, a DCP group; seronegative for AFP

and seropositive for DCP above 100mAU/mL and an AFP/DCP group; seropositive

for both AFP and DCP. Different clinical variables were compared among the

four groups. RESULTS: There were no significant differences among the groups

regarding age, viral markers or the presence of underlying cirrhosis. The

DCP group and the AFP/DCP group occurred more often in male patients and

they also tended to have a higher incidence of large hepatocellular

carcinoma measuring 3 cm or more in greatest dimension compared to the

Negative group and the AFP group. The AFP/DCP group showed higher incidences

of non-solitary hepatocellular carcinoma and larger hepatocellular carcinoma

measuring 3 cm or more in greatest dimension, and the presence of portal

thrombosis in comparison to the other three groups and also showed a shorter

survival. CONCLUSIONS: Hepatocellular carcinomas seropositive for DCP were

predominantly found in male patients, and hepatocellular carcinoma

seropositive for both DCP and AFP tended to be initially diagnosed at an

advanced stage which resulted in a shorter survival.

PMID: 14696467 [PubMed - in process]

[Guest guest]

Hepatogastroenterology. 2003 Nov-Dec;50(54):2072-8.

Clinical characteristics among patients with hepatocellular carcinoma

according to the serum levels of alpha-fetoprotein and des-y-carboxy

prothrombin.

Dohmen K, Shigematsu H, Irie K, Ishibashi H.

Clinical Research Center, National Nagasaki Medical Center, Nagasaki

856-8562, Japan. dohmenk@...

BACKGROUND/AIMS: Only limited amounts of data are available at present

regarding the clinical differences in cases of hepatocellular carcinoma who

have seropositivity or seronegativity for AFP (alpha-fetoprotein) and DCP

(des-y-carboxy prothrombin). In the current study we investigated the

different clinical variables in patients with hepatocellular carcinoma

according to the serum levels of AFP and DCP. METHODOLOGY: Analyses were

performed based on 168 consecutive patients with hepatocellular carcinoma

observed for 4 years between July 1997 and December 2000 at the Internal

Medicine Department, Saga Prefectural Hospital Koseikan. They were

retrospectively evaluated for the analysis in the study. They were

classified into four groups according to their serum levels of positivity

for AFP and DCP as follows: a Negative group; seronegative for both AFP

below 20 ng/mL and DCP below 40mAU/mL, an AFP group; seropositive for AFP

above 100 ng/mL and seronegative for DCP, a DCP group; seronegative for AFP

and seropositive for DCP above 100mAU/mL and an AFP/DCP group; seropositive

for both AFP and DCP. Different clinical variables were compared among the

four groups. RESULTS: There were no significant differences among the groups

regarding age, viral markers or the presence of underlying cirrhosis. The

DCP group and the AFP/DCP group occurred more often in male patients and

they also tended to have a higher incidence of large hepatocellular

carcinoma measuring 3 cm or more in greatest dimension compared to the

Negative group and the AFP group. The AFP/DCP group showed higher incidences

of non-solitary hepatocellular carcinoma and larger hepatocellular carcinoma

measuring 3 cm or more in greatest dimension, and the presence of portal

thrombosis in comparison to the other three groups and also showed a shorter

survival. CONCLUSIONS: Hepatocellular carcinomas seropositive for DCP were

predominantly found in male patients, and hepatocellular carcinoma

seropositive for both DCP and AFP tended to be initially diagnosed at an

advanced stage which resulted in a shorter survival.

PMID: 14696467 [PubMed - in process]

[Guest guest]

Hepatogastroenterology. 2003 Nov-Dec;50(54):2072-8.

Clinical characteristics among patients with hepatocellular carcinoma

according to the serum levels of alpha-fetoprotein and des-y-carboxy

prothrombin.

Dohmen K, Shigematsu H, Irie K, Ishibashi H.

Clinical Research Center, National Nagasaki Medical Center, Nagasaki

856-8562, Japan. dohmenk@...

BACKGROUND/AIMS: Only limited amounts of data are available at present

regarding the clinical differences in cases of hepatocellular carcinoma who

have seropositivity or seronegativity for AFP (alpha-fetoprotein) and DCP

(des-y-carboxy prothrombin). In the current study we investigated the

different clinical variables in patients with hepatocellular carcinoma

according to the serum levels of AFP and DCP. METHODOLOGY: Analyses were

performed based on 168 consecutive patients with hepatocellular carcinoma

observed for 4 years between July 1997 and December 2000 at the Internal

Medicine Department, Saga Prefectural Hospital Koseikan. They were

retrospectively evaluated for the analysis in the study. They were

classified into four groups according to their serum levels of positivity

for AFP and DCP as follows: a Negative group; seronegative for both AFP

below 20 ng/mL and DCP below 40mAU/mL, an AFP group; seropositive for AFP

above 100 ng/mL and seronegative for DCP, a DCP group; seronegative for AFP

and seropositive for DCP above 100mAU/mL and an AFP/DCP group; seropositive

for both AFP and DCP. Different clinical variables were compared among the

four groups. RESULTS: There were no significant differences among the groups

regarding age, viral markers or the presence of underlying cirrhosis. The

DCP group and the AFP/DCP group occurred more often in male patients and

they also tended to have a higher incidence of large hepatocellular

carcinoma measuring 3 cm or more in greatest dimension compared to the

Negative group and the AFP group. The AFP/DCP group showed higher incidences

of non-solitary hepatocellular carcinoma and larger hepatocellular carcinoma

measuring 3 cm or more in greatest dimension, and the presence of portal

thrombosis in comparison to the other three groups and also showed a shorter

survival. CONCLUSIONS: Hepatocellular carcinomas seropositive for DCP were

predominantly found in male patients, and hepatocellular carcinoma

seropositive for both DCP and AFP tended to be initially diagnosed at an

advanced stage which resulted in a shorter survival.

PMID: 14696467 [PubMed - in process]

[Guest guest]

Hepatogastroenterology. 2003 Nov-Dec;50(54):2072-8.

Clinical characteristics among patients with hepatocellular carcinoma

according to the serum levels of alpha-fetoprotein and des-y-carboxy

prothrombin.

Dohmen K, Shigematsu H, Irie K, Ishibashi H.

Clinical Research Center, National Nagasaki Medical Center, Nagasaki

856-8562, Japan. dohmenk@...

BACKGROUND/AIMS: Only limited amounts of data are available at present

regarding the clinical differences in cases of hepatocellular carcinoma who

have seropositivity or seronegativity for AFP (alpha-fetoprotein) and DCP

(des-y-carboxy prothrombin). In the current study we investigated the

different clinical variables in patients with hepatocellular carcinoma

according to the serum levels of AFP and DCP. METHODOLOGY: Analyses were

performed based on 168 consecutive patients with hepatocellular carcinoma

observed for 4 years between July 1997 and December 2000 at the Internal

Medicine Department, Saga Prefectural Hospital Koseikan. They were

retrospectively evaluated for the analysis in the study. They were

classified into four groups according to their serum levels of positivity

for AFP and DCP as follows: a Negative group; seronegative for both AFP

below 20 ng/mL and DCP below 40mAU/mL, an AFP group; seropositive for AFP

above 100 ng/mL and seronegative for DCP, a DCP group; seronegative for AFP

and seropositive for DCP above 100mAU/mL and an AFP/DCP group; seropositive

for both AFP and DCP. Different clinical variables were compared among the

four groups. RESULTS: There were no significant differences among the groups

regarding age, viral markers or the presence of underlying cirrhosis. The

DCP group and the AFP/DCP group occurred more often in male patients and

they also tended to have a higher incidence of large hepatocellular

carcinoma measuring 3 cm or more in greatest dimension compared to the

Negative group and the AFP group. The AFP/DCP group showed higher incidences

of non-solitary hepatocellular carcinoma and larger hepatocellular carcinoma

measuring 3 cm or more in greatest dimension, and the presence of portal

thrombosis in comparison to the other three groups and also showed a shorter

survival. CONCLUSIONS: Hepatocellular carcinomas seropositive for DCP were

predominantly found in male patients, and hepatocellular carcinoma

seropositive for both DCP and AFP tended to be initially diagnosed at an

advanced stage which resulted in a shorter survival.

PMID: 14696467 [PubMed - in process]